| |
July 18-19, 2023 | Jersey City, NJ This is the only communications event for peer learning and networking exclusively for the life science community.
Only two weeks left to Register!
|
|
Today's Big NewsJul 5, 2023 |
|
October 16-18, 2023 | Boston, MA The event is created with networking in mind and several opportunities where you can meet, connect and engage with your peers and grow your network. Save $346 on Registration with the Early Bird Rate!
|
|
| By Nick Paul Taylor AstraZeneca and Daiichi Sankyo’s attempt to repeat the success of Enhertu has delivered its first phase 3 data. The antibody-drug conjugate improved progression-free survival in lung cancer patients but, with the partners yet to share numbers and “some” patients suffering fatal adverse events, shares in AstraZeneca fell almost 6% in early trading in London. |
|
|
|
By Annalee Armstrong Once one of the hottest vessels in the pharma fleet, SHP2 inhibitors are starting to retreat from the seas as AbbVie joins the list of companies ending work on a collaboration with Jacobio to develop therapies for the target. |
By James Waldron Evotec has secured yet another contract from the Department of Defense. This time the U.S. government is committing $74 million for the development of monoclonal antibodies against mpox, chickenpox and smallpox. |
By Nick Paul Taylor Protagonist Therapeutics has shared a closer look at midphase data on its Johnson & Johnson-partnered oral peptide psoriasis drug candidate. The efficacy fell short of the high bar set by injectable treatments but, with the candidate offering the convenience of oral delivery, a phase 3 program is planned. |
By James Waldron Despite a two-year search for licensing partners for its hypertension med, Windtree Therapeutics has found itself in a Catch-22 situation that means development of the drug is stalled for the time being. |
By Nick Paul Taylor Sensorion’s bid to rebuild confidence in its hearing loss drug candidate SENS-401 has gathered another data point. After seeing the small molecule fail in one indication last year, the French biotech has now provided very early evidence that it may protect against hearing loss in another setting. |
By Helen Floersh A new study from researchers at the University of California San Diego School of Medicine has found one potentially beneficial combo for pancreatic cancer: Mirati Therapeutics' KRAS inhibitor adagrasib, known as Krazati, and Boehringer Ingelheim’s ERBB gene inhibitor afatinib, trade name Gilotrif. |
By Zoey Becker Boehringer Ingelheim's Cyltezo stands out from the crowd because it's the only Humira biosimilar to carry an interchangeability designation. |
By Andrea Park Medtronic has identified a vulnerability that could potentially allow hackers to access the cardiac device data stored in its Paceart Optima data workflow systems. |
By Zoey Becker Novartis is passing off the dry eye disease drop Xiidra to eye health specialist Bausch + Lomb in a $2.5 billion deal, another step in the company's overhaul as it focuses on five core areas. |
By Heather Landi The Biden administration issued a proposal Friday to cut reimbursements to home health providers by 2.2% next year, or an estimated $375 million less than 2023 payment levels. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss the American Diabetes Association's annual conference, plus a statement about transgender care, light therapy, and the rest of the week's headlines. |
|
|---|
|
|
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookThis eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBookTake a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
